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IN THE FIELD OF BONE REGENERATION, naturally derivedand synthetic polymers, ceramics, metals, and com-
posites are being used. On occasion, these so-called scaf-
fold materials are also provided with growth factors as
well as stromal cells in order to enhance their bone-form-
ing capacity. Demands on the scaffold properties largely
depend on the site of application and the function that
must be restored. For example, the ideal scaffold mater-
ial is mechanically strong, biocompatible, and biodegrad-
able; can be shaped easily; possesses interconnective
porosity; is osteoconductive or osteoinductive; and pro-
motes angiogenesis.1
Unfortunately, none of the currently used materials
meets all of the properties postulated. Some of the ma-
terials (e.g., polymers and ceramics that degrade quickly)
show an undesirable inflammatory response or foreign
body reaction. These reactions are associated with a re-
duced osteoinductive response. Other materials show a
lack of structural support and good mechanical charac-
teristics.
In view of the above, in our laboratory a series of stud-
ies is ongoing in which we explore the feasibility and ef-
ficacy of titanium fiber mesh as a scaffold material for
bone reconstructive purposes. Titanium is well known for
its excellent biocompatibility. This is expressed by two
major observations: (1) a favorable response of tissues to
titanium surfaces, and (2) the absence of allergic reac-
tions to titanium.2,3 For example, bone cells and miner-
alized bone matrix are laid down on titanium surfaces
without interposition of other tissues.2
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ABSTRACT
Little is known about the ability of peptide-coated surfaces to influence cell responses in vivo. Many
studies have demonstrated that peptide-modified surfaces influence cell responses in vitro. Integrins,
which bind specifically short peptide sequences, are responsible for these cell responses. In this way,
information can be transmitted to the nucleus through several cytoplasmic signaling pathways. The
peptide sequence Arg-Gly-Asp (RGD peptide) plays an important role in osteoblast adhesion. The
present study was designed to investigate new bone formation in a porous titanium (Ti) fiber mesh
implant, which was coated with cyclic RGD peptide. The RGD–Ti implants were inserted into the
cranium of a rabbit and were compared with porous titanium fiber mesh disks without RGD se-
quence (Ti) and with an open control defect. Histologic and histomorphometric examinations were
performed 2, 4, and 8 weeks postoperatively. A significant increase in bone formation, or bone in-
growth, was seen in the RGD–Ti group compared with the Ti group after 4 and 8 weeks. All con-
trol defects stayed open in all three periods. It was concluded that the use of cyclic RGD peptide in
combination with titanium fiber mesh has a positive effect on bone formation in vivo in a rabbit an-
imal model.
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The porous titanium fiber mesh as used in our studies
has several advantages relative to bulk titanium, such as
its flexibility and interconnective porosity. Flexibility
helps presumably to eliminate focal stresses by distrib-
uting the stresses between implant and tissue over a larger
area.3 The porosity of the fiber mesh, which can be var-
ied during fabrication, can influence the amount of bone
ingrowth into the material and allows a more normal
restoration of the bone, unlike nonporous implant mate-
rials.3
Proper bone growth also requires initial stability. The
frictional characteristics of porous titanium fiber mesh
when contacting bone exceed those of solid metal mate-
rials presently available. In the early postoperative period
these frictional and structural properties allow a high ini-
tial stability of the construct.
Although porous titanium fiber mesh is nondegradable,
it still offers several advantages over other materials by
its uniformity and structural continuity, as well as by its
strength, low stiffness, high porosity, corrosion resis-
tance, and high coefficient of friction.4 Nevertheless, pre-
vious studies have shown that the osteoconductive prop-
erties of the material are still insufficient to allow
complete closure of cranial defects in rats.5 Stromal bone
marrow cells have been seeded into the mesh porosity to
overcome this problem.5 Although the data confirmed
that this technique supports bone formation inside the
mesh, this cell-based approach is laborious and the out-
come is not completely predictable. Therefore, titanium
mesh has also been treated with bone growth-stimulating
factors, such as bone morphogenetic protein and trans-
forming growth factor-1.6–8 Despite favorable results in
rats, the disadvantage of the use of such morphogens is
the cost and reproducibility of the results in larger ani-
mals and humans.
An alternative to the above-mentioned approaches may
be the covalent coupling of ligands, such as peptides, to
the titanium mesh surface.9
The organic component of bone is composed of nu-
merous extracellular matrix proteins that serve multi-
ple roles in bone formation and homeostasis, ranging
from simple cell attachment to binding of hydroxyap-
atite. These extracellular matrix proteins interact with
a heterodimeric cell membrane receptor family, known
as integrins, that use multiple intracellular signaling
pathways. Arginine-glycine-aspartic acid, or RGD, is
a small peptide ligand that has high affinity for these
integrins and is the most extensively studied integrin-
stimulating peptide. It is known that RGD peptides in-
crease the overall adhesiveness of the surface for 
osteoblasts.10,11 In this way, they can essentially
mimic cell attachment activity of bone cells.12,13 It has
also been suggested that RGD peptide coating en-
hances titanium rod osseointegration in the rat and goat 
femur.14,15
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In the current study, the influence on bone formation
of a cyclic RGD peptide sequence coated on porous ti-
tanium fiber mesh was investigated. We evaluated the os-
teoconductive properties of porous titanium fiber mesh,
coated or not coated with covalently coupled RGD se-
quence, in a rabbit non-critical-size cranial defect model.
We hypothesized that adding this cycled RGD peptide to
the titanium fiber mesh would enhance the osteoconduc-
tive properties of this carrier material.
MATERIALS AND METHODS
Implant preparation
Sintered titanium fiber mesh implants (Bekaert, Zwe-
vegem, Belgium) with a volumetric porosity of 86%, a den-
sity of 600 g/m2, and a fiber diameter of 40 m, were used.
The prepared implants were disk-shaped with an outer
diameter of 8.0 mm, a thickness of 0.8 mm, and a weight
of approximately 33.5 mg. All implants were ultrasoni-
cally cleaned with isopropanol and 70% ethanol for 15
min, and then sterilized by gamma sterilization. Sixty im-
plants were prepared.
Subsequently, 30 of the titanium disks were coated
with 100 M cyclic RGD peptide (provided by Biomet
Deutschland [Darmstadt, Germany] and first synthesized
by the group of H. Kessler [Technical University of Mu-
nich, Munich, Germany]) containing a phosphonate an-
chor, in phosphate-buffered saline (PBS, pH 7.4). The
RGD was connected with a covalent bond, which creates
a connection. The titanium meshes were soaked in the
coating solution and the peptide was allowed to immo-
bilize overnight. After three washes with PBS the meshes
were dried and sterilized by gamma sterilization (≈25
kGy) and ready for implantation. Gamma sterilization
was confirmed by the manufacturer (Biomet Deutsch-
land) and was shown not to affect the activity of the pep-
tide coating.
Experimental study design
Thirty adult female New Zealand White rabbits
(2.5–3.5 kg) were used. National guidelines for the care
and use of laboratory animals were observed. In each
rabbit three cranial defects with an outer diameter of 8.0
mm were made (Fig. 1). The distance between the de-
fects was at least 5 mm. Treatments were titanium fiber
mesh (Ti), titanium fiber mesh loaded with RGD pep-
tide sequence (RGD–Ti) and an open control defect to
follow the regular healing process of the non-critical-
sized cranial defects.
The rabbits were killed at 2, 4, and 8 weeks (respec-
tively, groups I, II, and III; Table 1), and in each case the
skull with the implants was retrieved so that histologic
evaluation could be performed.
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Surgical procedure
Surgery was performed under general inhalation anes-
thesia. Anesthesia was induced by an intravenous injec-
tion of Hypnorm (fentanyl citrate [0.315 mg/mL] and flu-
anisone [10 mg/mL]) and atropine, and maintained by a
mixture of nitrous oxide, isoflurane, and oxygen through
a constant volume ventilator. To reduce the perioperative
infection risk, antibiotic prophylaxis (2.5% Baytril) was
given to the rabbits.
After anesthetization, the animals were immobilized
on their abdomen. Hair from the cranium was shaved and
the skin was disinfected with povidone-iodine.
From the nasal bone to the occipital protuberance, a
longitudinal incision was made. Thereafter, a midline
incision was created in the periosteum. Subsequently,
the periosteum was removed gently and lifted from the
parietal skull with a blunt instrument. Three cranial
full-thickness bone defects with an outer diameter of 8
mm were prepared with a dental trephine bur at low ro-
tation speed (1000–1500 rpm) in both sides of the pari-
etal bone. The drill depth was limited to 1.5 mm and
the cranial bone disks were carefully removed. During
the drilling procedure, saline was supplied as a coolant.
After this procedure, the RGD–Ti implant was inserted
according to a randomized implantation schedule in one
of the three defects in the skull (Table 2). The titanium
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fiber mesh without RGD was placed in the second de-
fect (Ti). The third defect was left open as a control in
order to monitor the regular healing capacity of this
non-critical-sized cranial defect in rabbits (Fig. 1). The
periosteum and skin were closed (tensionless) with Pro-
lene 4.0 sutures.
Histologic and histomorphometric evaluation
Skull bones containing the implants were retrieved for
histologic examination at the various times cited above.
Directly after retrieval, skulls were fixed in 4% buffered
formalin solution and dehydrated in a graded series of eth-
anol. Before embedding in methylmethacrylate (MMA),
the skulls were divided with a sawing machine into three
separate specimens containing one implant each. Finally,
thin sections (10 m) were prepared by a sawing micro-
tome technique after polymerization.16 All sections were
made in the frontal–caudal direction. The slides were
stained with methylene blue–basic fuchsin and observed
with a light microscope for histologic examination (Le-
ica Microsystems, Rijswijk, The Netherlands). At least
three sections from the central part of each implant were
evaluated.
Histologic evaluation consisted of a concise descrip-
tion of the observed specimens and a histomorphometric
analysis of the tissue response.
Histomorphometric evaluation was carried out by com-
puter-based image analysis (Leica QWin Pro image anal-
ysis system; Leica Microsystems). From each implant,
data were pooled and the mean was used for statistical
analysis.
The following histomorphometric parameters were as-
sessed for the Ti and RGD–Ti cranial implants (Fig. 2):
• The surface area where the titanium implant was in-
serted (the so-called region of interest [ROI])
• The bone surface area in the ROI (expressed as a
percentage of the ROI)
• The distance of bone ingrowth into the titanium fiber
mesh. This was calculated as the sum of ingrowths
at the right and left sides of the implants, divided by
the total length of the implant
For the open control defects only the maximum gap as
left at the end of the respective implantation times was
measured.
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FIG. 1. Three cranial full-thickness bone defects with an outer
diameter of 8 mm (RGD–Ti, Ti, and open).
TABLE 1. NUMBER OF ANIMALS, DEFECT SIZE, AND IMPLANTATION TIME
Defect size Number of defects Implantation time
Group (mm) (RGD–Ti, Ti, open) (weeks)
I (n  10) 8.0 3 2
II (n  10) 8.0 3 4
III (n  10) 8.0 3 8
Statistical analysis
All measurements were statistically evaluated with
GraphPad Instat 3.05 software (GraphPad Software, San
Diego, CA), using an unpaired Student t test with Welch
correction to compare untreated Ti with RGD-treated Ti
specimens for each implantation time. All data were
tested for normality. Differences were considered signif-
icant at p values less than 0.05.
RESULTS
Macroscopic evaluation
All 30 animals survived the implantation period and re-
mained in good health. At retrieval no macroscopic signs
of inflammation or adverse tissue reaction were seen around
any of the 90 defects. All implant sites and empty control
defects could be easily located. Each implant remained
seated at the original site and they were all covered by pe-
riosteum. Bone formation could be seen macroscopically
in most of the specimens. The newly formed bone appeared
normal. No gross macroscopic differences could be ob-
served between the RGD–Ti and Ti groups.
Histologic and histomorphometric evaluation
Two weeks. All of the control defects (10) were open
after 2 weeks. New bone formation started mainly at the
edges of the defect (Fig. 3). The morphological appear-
ance and thickness of the newly formed bone differed
from the original bone. Histomorphometry revealed that
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the bone had covered 52  8% of the length of the orig-
inal control defect size.
Also, none of the titanium defects were closed (cov-
ered with bone over the whole defect). In all Ti and
RGD–Ti implants, blood vessel ingrowth and fibrous tis-
sue formation were present. Blood vessel ingrowth in the
RGD–Ti group appeared to be more prominent than in
the Ti group. No inflammatory cells or fibrous tissue were
present in or around the surface of both types of implant.
After 2 weeks, 12  5% of the RGD–Ti fiber mesh
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RGD–Ti Ti Control defect
Rabbit no. and location skull location location location No defect
1, 5, 9, 13, 17, 21, 25, 29 1 2 3 4
2, 6, 10, 14, 18, 22, 26, 30 2 3 4 1
3, 7, 11, 15, 19, 23, 27 3 4 1 2





TABLE 2. RANDOMIZED IMPLANTATION SCHEDULE
= ROI
= Bone Surface Area
= Ingrowth L+R/ Total
   length
FIG. 2. Histomorphometric parameters of Ti and RGD–Ti
cranial implants (region of interest [ROI], bone surface area,
and bone ingrowth in length).
was covered with bone with a trabecular structure, start-
ing at the edges, and 8  6% of the Ti fiber mesh with-
out RGD was covered (no significant difference; Table
3). There was also no significant difference between the
total ingrowth (percent ingrowth of the total length of the
implant) of the RGD–Ti group (58  24%) and the Ti
group (44  26%) (Table 4).
Representative examples of light microscopic sections
of control, RGD–Ti, and Ti implants 2 weeks postim-
plantation are depicted in Fig. 3.
Four weeks. All of the empty control defects were still
open after 4 weeks (n  10). The newly formed bone cov-
ered 52  12% of the total length of the original control
defect size (Fig. 4). The contour, that is, thickness, of the
ingrown bone differed from the original bone. Inside the
empty defect space, fibrous tissue was present and blood
vessel invasion had occurred. Always, a fibrous tissue cap-
sule could be observed at the periphery of the bone defect.
The Ti and RGD–Ti mesh implants were also sur-
rounded with a fibrous tissue capsule. No inflammatory
cells were seen in or around the surfaces of the implants.
There was no observable increase in thickness of the cap-
sule from week 2 to week 4.
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After 4 weeks there was significantly more bone sur-
face area in the RGD–Ti group (12  4%) compared with
the Ti group (6  5%; Table 3). Further, total bone in-
growth in the RGD–Ti group was 71  17% and in the
Ti group it was 50  20%, which is significantly differ-
ent as well (Table 4).
Figure 4 shows typical histologic slides of control,
RGD–Ti, and Ti implants 4 weeks postimplantation.
Eight weeks. All of the empty defects were still open
after 8 weeks. New bone formation covered 64  12%
of the total length of the control defect (Fig. 5). The newly
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TABLE 3. BONE SURFACE AREA IN RGD–TI AND TI
SCAFFOLDS 2, 4, AND 8 WEEKS POSTIMPLANTATION
Time
postimplantation (weeks) RGD–Ti Ti
2 12  50 8  6
4 12  40 6  5
8 18  10 10  7
aRelative to region of interest (ROI).
Area of bone (%)a
formed bone still differed in thickness compared with the
original bone. A fibrous tissue capsule was maintained
at the outside of the gap.
One of the RGD–Ti implants was completely covered
with bone over its total length. Further, blood vessel in-
growth and fibrous tissue encapsulation were compara-
ble between the 2- and 4-week specimens.
After 8 weeks, 18  10% of the RGD–Ti fiber mesh
surface area was occupied by bone, compared with 10 
7% of the titanium fiber mesh without RGD (Table 3).
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This difference was not significant (p  0.057). How-
ever, the total bone ingrowth percentage in the RGD–Ti
group (71  21%) was significantly greater than in the
Ti group (52  16%) (Table 4).
Figure 5 shows the light microscopic appearance of
control, RGD–Ti, and Ti implants 8 weeks postimplan-
tation.
DISCUSSION
In this study, we investigated the effect of RGD-coated
titanium fiber mesh on bone formation in vivo at three
different times postimplantation. Histomorphometric
analysis determined that 18  10% of the RGD–Ti fiber
mesh was occupied with bone after 8 weeks compared
with 10  7% of the titanium fiber mesh without RGD
(not significant; p  0.057). Nevertheless, after 4 weeks
there was significantly more bone surface area in the
RGD–Ti group (12  4%) compared with the Ti group
(6  5%; Table 3). A significant increase in ingrowth
(length) after 4 and 8 weeks occurred as well, when com-
pared with the reference material (uncoated titanium fiber
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TABLE 4. BONE INGROWTHa IN RGD–TI AND TI
SCAFFOLDS 2, 4, AND 8 WEEKS POSTIMPLANTATION
Time
postimplantation (weeks) RGD–Ti Ti
2 58  24 44  26
4 71  17 50  20
8 71  21 52  16
Bone ingrowth (right  left)/
total length of implant (%)
FIG. 4. Light microscopy overview of (A) control defect, (B) RGD–Ti scaffold (B1 shows limited bone ingrowth; B2 shows
bone overgrowth of mesh structure), and (C) Ti-scaffold (C1 shows limited bone growth; C2 shows deep bone penetration in





mesh). We must also note that all control defects stayed
open until 8 weeks postimplantation. This emphasizes the
relevance of our model. Evidently, the Ti scaffolds also
did not hamper or interfere in a negative way with the
bone-healing process.
Bone cell adhesion and migration are known to play
an important role during the biological processes under-
lying bone healing and bone regeneration. Cell adhesion
peptides, such as RGD, are supposed to play a role in the
control of bone cell proliferation and differentiation. The
peptides must be covalently attached to a suitable carrier
material in order to be used in implant surgery. The re-
sults, as obtained in the current study, confirm the hy-
pothesis that coating cycled RGD peptide on titanium
fiber mesh will enhance the osteoconductive properties
of this carrier material. The results corroborate with other
studies. For example, Ferris et al.14 demonstrated a sig-
nificant increase in new bone thickness around RGDC
(Arg-Gly-Asp-Cys)-modified surfaces of polished tita-
nium rods in rat femur 2 and 4 weeks after implantation.
They measured a significantly thicker shell of newly
formed bone around the implant as soon as 2 weeks
INFLUENCE OF RGD-LOADED TITANIUM IMPLANTS
postimplantation, but using another animal model and an-
other titanium implant and implantation site.
Elmengaard et al.17 showed that a cyclic RGD coating
on unloaded press-fit titanium implants has an osteocon-
ductive effect only directly at the interface 4 weeks
postimplantation (implanted in the tibia of a dog model).
Also, Schliephake et al. found an increase in bone–im-
plant contact from 1 to 3 months postoperatively in a
group of RGD-coated implants, using a combination of
collagen and RGD on dental implants in the mandibles
of 10 beagle dogs.18 However, similar to our study,
Schliephake et al. showed a large degree of variation in
bone contact rates within the various experimental
groups, resulting in a decreased level of significance. The
experimental model can be an important variable for this
phenomenon. Tripeptide RGD has been shown to en-
hance in vitro the adhesion and spreading of fibroblasts,
endothelial cells, smooth muscle cells, and osteoblasts
when this biomolecule was grafted on various sur-
faces.19–22 Concerning the effect of RGD peptides on os-
teoblast cell differentiation, integrin-mediated cell bind-
ing seems to be the essential parameter. In particular,
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FIG. 5. Light microscopy overview of (A) control defect, (B) RGD–Ti scaffold (B1 shows bone overgrowth; B2 shows bone
ingrowth in mesh structure), and (C) Ti-scaffold (C1 shows no bone ingrowth; C2 shows limited bone ingrowth in mesh poros-





v3 and v5 integrin-selective RGD peptide ligands
are responsible for mediating the initial adhesion and in-
creased synthesis of mineralized matrix.23 Bernhardt et
al. also indicated that RGD peptides were capable of gen-
erating signals for the specific microenvironment around
titanium implants in the femur of a goat and thus accel-
erated the bone formation process.15 Nevertheless, a de-
cisive factor in the cell attachment-promoting activity of
surface-bound RGD peptide is, of course, the availabil-
ity of a sufficient amount of free bone-forming cells. This
may have been the major problem in our in vivo study.
Periosteal osteo- and chondrogenesis is important for
bone defect healing. In our study design, the periosteum
was first lifted from the skull bone and at the end of the
procedure was sutured back over the mesh implant to its
original position. The periosteum consists of two layers:
a fibrous outer layer and, bordering the bone, a cambium
layer, which contains specific osteogenic and chondro-
genic precursor cells.24 Therefore, maintenance of this
cambium layer may be essential for bone healing to oc-
cur in the mesh implant after closure of the periosteum
at the end of the implant installation. However, in rab-
bits this layer is difficult to retain during surgery, result-
ing in delayed healing.25 Besides preservation of the cam-
bium layer, skull bone is composed mainly of cortical
bone with a minimal portion of marrow-rich cancellous
bone. In addition, the amount of contact between the
mesh scaffold and bone defect wall was limited to a few
40–m-thick titanium fibers because of the specific mor-
phological structure of the mesh material. Apparently,
this also did not promote the migration of bone cells into
the mesh porosity.
Besides the experimental model, another critical is-
sue dealing with the modification of implant surfaces
by peptides is the final selectivity of the peptides used.
Besides bone cells, the adhesion of other cell types can
be promoted. Also, multiple ligands may be required for
a full cell adhesion response.26 In view of this, two rel-
evant parameters for the final biological effect of grafted
RGD peptides are the competitive adsorption of a sec-
ond protein from the surrounding body fluid and the
RGD peptide surface concentration.27 The second ad-
sorbed protein can result in inefficient cell adhesion,
and an increase in RGD peptide surface concentration
has been shown to result in increased cell proliferation
with, at the same time, reduced matrix production.27 Un-
fortunately, we do not know whether optimum surface
conditions existed for early differentiation and pheno-
typic expression on our RGD-coated titanium fiber
meshes.28 In view of the above, it must also be noted
that other implant materials are available with perhaps
better osteoconductive properties as compared with Ti
mesh. Most of these materials belong to the class of cal-
cium phosphate (CaP) ceramics. Unfortunately, these
materials lack the advantageous mechanical properties
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of titanium, the result being that titanium, with its im-
provement in osteoconductive behavior, is still attrac-
tive from the final clinical application perspective.29
CONCLUSION
In conclusion, cyclic RGD peptide in combination with
titanium fiber mesh has a positive effect, compared with
titanium fiber mesh alone, on bone formation in vivo af-
ter 4 and 8 weeks when implanted in the skull of New
Zealand White rabbits. Nevertheless, the amount of bone
formation inside the mesh pores was still limited and fur-
ther studies are required to optimize the bone biological
effect of cyclic RGD peptide grafted on titanium fiber
mesh scaffold.
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